Back to Search Start Over

Safety, pharmacokinetics, metabolism and radiation dosimetry of 18 F-tetrafluoroborate ( 18 F-TFB) in healthy human subjects.

Authors :
Jiang H
Schmit NR
Koenen AR
Bansal A
Pandey MK
Glynn RB
Kemp BJ
Delaney KL
Dispenzieri A
Bakkum-Gamez JN
Peng KW
Russell SJ
Gunderson TM
Lowe VJ
DeGrado TR
Source :
EJNMMI research [EJNMMI Res] 2017 Oct 27; Vol. 7 (1), pp. 90. Date of Electronic Publication: 2017 Oct 27.
Publication Year :
2017

Abstract

Background: <superscript>18</superscript> F-Tetrafluoroborate ( <superscript>18</superscript> F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity <superscript>18</superscript> F-TFB in healthy human subjects.<br />Methods: <superscript>18</superscript> F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of <superscript>18</superscript> F-TFB (333-407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety.<br />Results: <superscript>18</superscript> F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of <superscript>18</superscript> F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant <superscript>18</superscript> F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of <superscript>18</superscript> F-TFB was prominent. Metabolic stability was evidenced by low accumulation of <superscript>18</superscript> F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant).<br />Conclusions: This initial study in healthy human subjects showed <superscript>18</superscript> F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with <superscript>18</superscript> F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

Details

Language :
English
ISSN :
2191-219X
Volume :
7
Issue :
1
Database :
MEDLINE
Journal :
EJNMMI research
Publication Type :
Academic Journal
Accession number :
29080017
Full Text :
https://doi.org/10.1186/s13550-017-0337-5